Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareBOM:530549 -2.88%76 Dividend Yield % is 0.08% as of Jul. 18, 2026, which is 60% below its 10-year median of 0.20. GuruFocus rates BOM:530549 with a GF Score™ of 76/100 and a GF Value™ of ₹387.34 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 514 Drug Manufacturers companies, Shilpa Medicare ranks worse than 97.86% on this metric.
As of today (2026-07-18), the Trailing Annual Dividend Yield of Shilpa Medicare is 0.08%.
Warning Sign:
Shilpa Medicare Ltd stock Dividend Yield % is close to 10-year low.
The historical rank and industry rank for Shilpa Medicare's Dividend Yield % or its related term are showing as below:
BOM:530549'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.08 Med: 0.2 Max: 0.78
Current: 0.08
During the past 13 years, the highest Dividend Yield of Shilpa Medicare was 0.78%. The lowest was 0.08%. And the median was 0.20%.
BOM:530549's Dividend Yield % is ranked worse than 97.86% of 514
companies
in the Drug Manufacturers industry
Industry Median: 1.945
vs BOM:530549: 0.08
During the past 3 years, the average Dividends Per Share Growth Rate was -3.10% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Shilpa Medicare was 56.50% per year. The lowest was -19.40% per year. And the median was 21.80% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Shilpa Medicare's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530549 vs ZTS, UTHR: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Shilpa Medicare Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 0.500000
2025-09-17
2025-09-17
0000-00-00
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Shilpa Medicare's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (BOM:530549) has a Dividend Yield % of 0.08% as of Jul. 18, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Shilpa Medicare and its competitors. This is 60% below median its historical median of 0.20. Over the past decade, Shilpa Medicare's Dividend Yield % has ranged from 0.08 to 0.78. According to the industry distribution chart, Shilpa Medicare ranks #503 out of 514 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is Shilpa Medicare's Dividend Yield % too high?
Shilpa Medicare's current Dividend Yield % of 0.08% is 60% below median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.78. The Drug Manufacturers industry median Dividend Yield % is 1.95. Shilpa Medicare's value of 0.08% is 95.9% below this industry median. Based on the distribution chart, Shilpa Medicare ranks #503 out of 514 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #503 out of 514 companies for Dividend Yield %. This places Shilpa Medicare in the lower half of its industry. The industry median Dividend Yield % is 1.95. Shilpa Medicare's value of 0.08% is 95.9% below this benchmark. Historically, Shilpa Medicare's own Dividend Yield % has ranged from 0.08 to 0.78 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 1.95, Shilpa Medicare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.95, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current Dividend Yield % of 0.08% is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current Dividend Yield % is 0.08%, which is 60% below median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (BOM:530549) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.34, compared to a current price of ₹619.55 — trading 59.9% above its estimated fair value. The current Dividend Yield % is 0.08%, which is 60% below median its 10-year median of 0.20 and 95.9% below the Drug Manufacturers industry median of 1.95. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Shilpa Medicare (BOM:530549), the current Dividend Yield % is 0.08% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (BOM:530549) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹619.55 is trading 59.9% above its estimated GF Value™ of ₹387.34.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for BOM:530549:
Dividend Yield %: 0.08% (60% below median its 10-year median of 0.20)
GF Value™: ₹387.34 vs. price of ₹619.55 (59.9% above fair value)
Industry Position: 95.9% below the Drug Manufacturers median (#503 of 514)
No single metric tells the full story. See the BOM:530549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for BOM:530549
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530549 has been successfully added to your 
